

CYTOKINETICS INC  
Form 8-K  
March 24, 2008

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 24, 2008

Cytokinetics, Incorporated

(Exact name of registrant as specified in its charter)

Delaware

000-50633

94-3291317

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

280 East Grand Avenue, South San Francisco,  
California

94080

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(650) 624 - 3000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 8.01 Other Events.**

Cytokinetics, Incorporated (the "Company") issued a press release announcing positive results from an analysis of the first two patient cohorts of the Company's ongoing Phase IIa clinical trial evaluating CK-1827452, administered intravenously in patients with stable heart failure. This Phase IIa clinical trial is a multi-center, double-blind, randomized, placebo-controlled, dose-escalation, pharmacokinetic and pharmacodynamic trial of CK-1827452. The primary objective of this trial is to evaluate the safety and tolerability of CK-1827452 administered as an intravenous infusion to stable heart failure patients. The secondary objectives of this trial are to establish a relationship between the plasma concentration and pharmacodynamic effects of CK-1827452 and to determine the pharmacokinetics of CK-1827452 in stable heart failure patients.

Data from the first two cohorts of this ongoing Phase IIa clinical trial of CK-1827452 will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology to be held June 14-17, 2008 in Milan, Italy.

Cytokinetics will be hosting an Investor Breakfast entitled "Investigators' Perspectives on Measurements of Cardiac Performance" on Monday, March 31st from 7:00 a.m. – 8:00 a.m. Central Time in the Mayfair Room at the Westin Michigan Avenue Hotel in Chicago, Illinois. The presentation and accompanying slides will be simultaneously webcast and a live audio of the forum will also be available to investors, members of the news media and the general public. The press release contains information regarding the access to the webcast.

A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits of this Current Report on Form 8-K:

Exhibit No. Description

-----  
99.1 Press release, dated March 24, 2008.

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cytokinetics, Incorporated

*March 24, 2008*

*By: Sharon Surrey-Barbari*

---

*Name: Sharon Surrey-Barbari  
Title: Senior Vice President, Finance and Chief Financial  
Officer*

---

**Top of the Form**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release, dated March 24, 2008